Zobrazeno 1 - 10
of 382
pro vyhledávání: '"Ravulizumab"'
Autor:
Stefan Quasthoff
Publikováno v:
Clinical Case Reports, Vol 12, Iss 11, Pp n/a-n/a (2024)
Key Clinical Message This unique case of generalized myasthenia gravis shows sustained stability of a patient's condition for 3 years with eculizumab/ravulizumab treatment following 16 years of refractory disease. It highlights the long‐term effect
Externí odkaz:
https://doaj.org/article/ef7aefbd301247cbbbb05b3fa6569cdc
Autor:
Michal Nowicki, Nikoleta Printza
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 11 (2024)
This summary gives an overview of three published articles that report the results of research studies of ravulizumab, an approved treatment for people with atypical hemolytic uremic syndrome (often shortened to aHUS). This is a rare and serious c
Externí odkaz:
https://doaj.org/article/4472bc33e4da435a92f5fdf66a2f6cb5
Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies
Autor:
Florencia Aguirre, Renata Andrade
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 11 (2024)
What is this summary about? Generalized myasthenia gravis (often shortened to gMG) is a rare health condition that causes muscular weakness. This summary gives an overview of three published articles that report the results of research studies of
Externí odkaz:
https://doaj.org/article/67bb5efd245f4d099f051f4d0371a063
Autor:
Kristina Schönfelder, Lucas Kühne, Lena Schulte-Kemna, Jessica Kaufeld, Hana Rohn, Andreas Kribben, Bernd Schröppel, Paul T. Brinkkötter, Anja Gäckler
Publikováno v:
BMC Nephrology, Vol 25, Iss 1, Pp 1-8 (2024)
Abstract Background The complement factor 5 (C5)-inhibitor eculizumab has been established as standard-of-care for the treatment of atypical hemolytic uremic syndrome (aHUS). In 2021, the long-acting C5-inhibitor ravulizumab was approved, extending i
Externí odkaz:
https://doaj.org/article/064aa74fbb6e4cf0a385f7f62fede2f5
Autor:
Stacey L. Clardy, Sean J. Pittock, Orhan Aktas, Jin Nakahara, Noriko Isobe, Diego Centonze, Sami Fam, Adrian Kielhorn, Jeffrey C. Yu, Jeroen Jansen, Ina Zhang
Publikováno v:
Neurology and Therapy, Vol 13, Iss 3, Pp 535-549 (2024)
Abstract Introduction Anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) is a complement-mediated autoimmune disease in which unpredictable and relapsing attacks on the central nervous system cause irreversib
Externí odkaz:
https://doaj.org/article/8aae6e477a6f451e84e0e1f1a4138a6b
Autor:
Di Matteo S, Freilone R, Bruno GM, Notaro R, Moumene S, Martone N, Teruzzi C, Ciccarone A, Colombo GL
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 16, Pp 225-232 (2024)
Sergio Di Matteo,1 Roberto Freilone,2 Giacomo Matteo Bruno,1,3 Rosario Notaro,4 Sabrin Moumene,1 Nicoletta Martone,5 Cristina Teruzzi,5 Antonio Ciccarone,1 Giorgio Lorenzo Colombo1,3 1Center of Research, SAVE Studi - Health Economics and Outcomes Res
Externí odkaz:
https://doaj.org/article/4629608afc194b81af209a6a659bb5e2
Autor:
V. D. Latyshev, Z. T. Fidarova, R. V. Ponomarev, N. V. Tsvetaeva, E. A. Mikhaylova, E. A. Lukina, E. N. Parovichnikova
Publikováno v:
Онкогематология, Vol 19, Iss 1, Pp 83-91 (2024)
Background. Paroxysmal nocturnal hemoglobinuria is a rare clonal disease of the hematopoietic system, with the key manifestations of hemolytic anemia, a high thrombosis rate, and bone marrow failure. Despite the high efficacy of C5‑inhibitors in in
Externí odkaz:
https://doaj.org/article/719811036e4c4f839846b9282e0ac275
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
PurposeTo describe the early experience of ravulizumab use in acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR+ve gMG).MethodsThis multicenter retrospective study included AChR+ve gMG patients who were treated with ravuliz
Externí odkaz:
https://doaj.org/article/d2676b2195924eeea1677199cb829f5d
Autor:
Kazuki Sakurai, Kei Saito, Shunsuke Hatta, Yuna Katsuoka, Kuniaki Meguro, Hisayuki Yokoyama, Toru Izumi
Publikováno v:
Clinical Case Reports, Vol 12, Iss 5, Pp n/a-n/a (2024)
Key Clinical Message Haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide is an alternative treatment for aplastic anemia–paroxysmal nocturnal hemoglobinuria (PNH) syndrome with poor prognostic factors.
Externí odkaz:
https://doaj.org/article/214ccb1defc349c3abfc7d42a37f1825
Autor:
Yara Maria da Silva Pires, Aline de Fátima Bonetti, Jessica Telma Ciecilinsky, Astrid Wiens Souza
Publikováno v:
Clinical Immunology Communications, Vol 3, Iss , Pp 37-41 (2023)
Paroxysmal nocturnal hemoglobinuria (PNH) is a non-malignant clonal disorder of the pluripotent hematopoietic stem cell. Currently, Eculizumab, Ravulizumab, and Pegcetacoplan are the approved drugs to treat PNH. In order to assess the efficacy and sa
Externí odkaz:
https://doaj.org/article/4894484c192d488388ae83c7c43540e1